<DOC>
	<DOCNO>NCT00002207</DOCNO>
	<brief_summary>The purpose study compare effectiveness take didanosine ( ddI ) day plus stavudine ( d4T ) twice day take ddI twice day plus d4T twice day . This study also examine safety give ddI d4T short-term .</brief_summary>
	<brief_title>A Comparison Two Dose Levels Didanosine Used Combination With Stavudine HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize receive ddI give either qd bid combination d4T give bid ( dos specify ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 cell count least 100 cells/mm3 . Plasma HIV RNA count 10,000 copies/ml within 14 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Presence newly diagnose AIDSdefining opportunistic infection require acute therapy time enrollment . Bilateral peripheral neuropathy sign symptom bilateral peripheral neuropathy great equal Grade 2 time screen . Inability tolerate oral medication . Any clinical condition would preclude compliance dosing requirement . Patients follow prior condition exclude : History acute chronic pancreatitis . Intractable diarrhea ( 6 loose stools/day 7 consecutive day ) within 30 day prior study entry . Proven suspect acute hepatitis within 30 day prior study entry . 1 . Potent neurotoxic drug , vincristine thalidomide . Other antiHIV therapy . 1 . Prophylaxis pneumocystis carinii pneumonia ( PCP ) strongly recommend patient CD4 cell count less equal 200/mm3 prior episode PCP . Immunizations recommend ACIP routine practice . Erythropoietin GCSF allow myelosuppression emerges study . 1 . Any antiretroviral therapy . Agents significant systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic , cytotoxic potential within 3 month study entry . 1 . Any prior antiretroviral therapy . Agents significant systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic , cytotoxic potential within 3 month study entry . Active alcohol substance abuse would prevent adequate compliance would increase risk pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>